Becton Dickinson
BDX
$185.92
+1.65%
Becton, Dickinson and Co. (BDX) is a global medical technology company that manufactures and sells a broad portfolio of medical devices, instrument systems, and reagents, organized across four segments: Medical Essentials (35% of sales, including catheters, syringes, and infection prevention), Connected Care (24%, anchored by the Alaris infusion pump and Pyxis dispensing platform), Biopharma Systems (13%, prefillable syringes and autoinjectors), and Interventional (29%, spanning surgery, peripheral vascular, and urology). As one of the largest and most diversified med-tech players in the world, BDX is distinct for its razor-and-razorblade hospital supply model, entrenched hospital relationships, and scale-driven cost advantages, with more than 60% of revenue generated in the United States. The current investor narrative centers on a sharp earnings-quality debate: the company posted a strong fiscal Q2 2026 beat and raised its full-year profit outlook while naming a new CFO, yet the quarter also included a GAAP net loss of $311 million and a 10.6% year-over-year revenue decline, leaving analysts split between bulls citing operational momentum and skeptics wary of margin sustainability and one-time charges. With the stock down roughly 6.7% over the past year despite a 21.6% three-month rally, the market is actively debating whether BDX is a genuine turnaround story or a value trap in a med-tech sector that has broadly outperformed.…
BDX
Becton Dickinson
$185.92
Related headlines
Investment Opinion: Should I buy BDX Today?
We assign a Hold rating on BDX, balancing its attractive forward valuation and strong cash flow against significant earnings quality concerns and revenue decline. The analyst consensus is Buy with an average target of $195.67, implying 10% upside, but the recent GAAP net loss and 10.6% revenue decline warrant caution. The core thesis is that BDX is a turnaround play with a discounted forward PE of 13.4x, but execution risks remain high.
Supporting evidence includes: 1) Forward PE of 13.4x is well below the trailing PE of 25.2x, suggesting expected earnings recovery; 2) Free cash flow of $3.14 billion provides flexibility; 3) Dividend yield of 2.84% is attractive for income investors; 4) Analyst target of $195.67 offers 10% upside. However, the net margin of 7.68% and operating margin of 11.8% are below historical levels, and the negative PEG ratio reflects lack of growth.
The biggest risks are: 1) Continued revenue decline could lead to further earnings misses; 2) Margin pressure from one-time charges and operational inefficiencies; 3) High short interest (short ratio 5.76) indicates bearish sentiment. The rating would upgrade to Buy if revenue growth turns positive and operating margins recover above 15%, or downgrade to Sell if revenue declines accelerate and free cash flow deteriorates. Relative to its history, BDX appears undervalued on a forward basis but fairly valued on trailing metrics, making it a hold for now.
Sign up to view all
BDX 12-Month Price Forecast
BDX presents a balanced risk/reward profile. The stock is cheap on forward earnings, but the recent revenue decline and GAAP loss highlight operational challenges. The base case (55% probability) sees the stock reaching $185-200 as the company stabilizes. The bull case (25%) relies on a successful turnaround, while the bear case (20%) reflects the risk of a deeper decline. We would upgrade to bullish if revenue growth turns positive and margins expand, and downgrade to bearish if revenue declines accelerate or free cash flow deteriorates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $195.67 and implied upside of +5.2% versus the current price.
Average Target
$195.67
0 analysts
Implied Upside
+5.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$170 - $225
Analyst target range
Bulls vs Bears: BDX Investment Factors
The bull case rests on BDX's deeply discounted forward PE of 13.4x, strong free cash flow of $3.14 billion, and analyst consensus target of $195.67 (10% upside). The bear case emphasizes the 10.6% revenue decline, a GAAP net loss of $311 million, and persistent underperformance versus the market. Currently, the bear evidence appears stronger on fundamentals, but the bull case is gaining traction with the recent 21.6% three-month rally and operational beat. The single most important tension is whether the Q2 revenue decline and net loss are temporary anomalies or signs of structural deterioration; resolution of this debate will likely determine the stock's direction over the next year.
Bullish
- Analyst consensus sees 10% upside: 12 analysts rate BDX a buy with an average target price of $195.67, implying roughly 10% upside from the current $177.85. The high target of $225 suggests some analysts see a path to a 26.5% gain, indicating confidence in the turnaround narrative.
- Forward PE of 13.4x is deeply discounted: BDX trades at a forward PE of just 13.38x based on estimated EPS of $16.35, a steep discount to the broader med-tech sector and its own trailing PE of 25.2x. This low multiple suggests the market is pricing in significant pessimism that may reverse if earnings normalize.
- Strong free cash flow generation: BDX generated $3.14 billion in trailing free cash flow, which comfortably covers its dividend payout ratio of 71.3% and provides ample liquidity for debt reduction or reinvestment. This cash generation underpins the 2.84% dividend yield and supports the investment-grade balance sheet.
- Momentum has turned positive: The stock has rallied 21.6% over the past three months, outperforming the S&P 500 by 18.6 percentage points, and is up 11.6% over six months. This recent strength suggests a potential inflection point after a prolonged period of underperformance.
Bearish
- Revenue declined 10.6% year-over-year: Fiscal Q2 2026 revenue fell 10.6% YoY to $4.71 billion, a sharp contraction that raises questions about the company's growth trajectory. This decline is particularly concerning given the essential nature of BDX's products, suggesting possible market share loss or pricing pressure.
- GAAP net loss of $311 million: Despite a headline earnings beat, BDX reported a GAAP net loss of $311 million in Q2 2026, with a negative net income ratio of -6.6%. This loss was driven by one-time charges and a significant drop in operating income to just $94 million (1.99% operating margin), highlighting earnings quality concerns.
- Valuation metrics show distress: The PEG ratio is deeply negative at -37.04, and the trailing PE of 25.2x is elevated relative to the company's weak earnings. The price-to-sales ratio of 1.93 and EV/EBITDA of 12.2 are not particularly cheap for a company with declining revenue.
- Significant underperformance versus market: BDX has underperformed the S&P 500 by 22.9 percentage points over the past year and by 20.8 percentage points year-to-date. This persistent relative weakness suggests deep-seated issues that may not be resolved quickly.
BDX Technical Analysis
Beta
0.28
0.28x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$128-$193
Price range past year
Annual Return
+0.1%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | +1.4% | -2.4% |
| 3m | +31.3% | +2.2% |
| 6m | +18.8% | +14.8% |
| 1y | +0.1% | +14.6% |
| ytd | -4.6% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
Quarterly Revenue
$4.7B
2026-03
Revenue YoY Growth
-10.6%
YoY Comparison
Gross Margin
45.7%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
PE
25.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~55x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
BDX faces notable financial and operational risks. The company reported a GAAP net loss of $311 million in Q2 2026, with operating income collapsing to $94 million (1.99% operating margin) from $546 million a year earlier. Revenue declined 10.6% year-over-year to $4.71 billion, and the current ratio of 1.11 indicates tight liquidity. With a debt-to-equity ratio of 0.755 and interest expense of $149 million in the quarter, the company's leverage could become burdensome if earnings do not recover. Additionally, the payout ratio of 71.3% leaves little room for dividend growth without improved profitability.
Market and competitive risks are significant. BDX trades at a trailing PE of 25.2x despite weak earnings, and its forward PE of 13.4x may be misleading if earnings estimates are too optimistic. The stock's beta of 0.276 suggests low correlation with the market, but sector rotation away from healthcare could pressure the shares. The med-tech sector has broadly outperformed, yet BDX has lagged, underperforming the S&P 500 by 22.9 percentage points over the past year. Competitive threats in infusion pumps and hospital supplies, plus potential regulatory changes, add to the uncertainty.
The worst-case scenario involves a continued decline in revenue and margins, leading to further earnings misses and analyst downgrades. If BDX fails to stabilize its core segments, the stock could retest its 52-week low of $127.59, representing a 28.3% decline from the current price of $177.85. The analyst low target of $170 offers a less severe downside of 4.4%, but a more bearish outcome could see the stock fall to $150 or lower, a 15.7% drop. Given the max drawdown of 33% over the past year, investors should be prepared for significant volatility.
FAQ
The key risks include: 1) Financial risk: revenue declined 10.6% YoY and the company posted a $311 million net loss, with a high payout ratio of 71.3% limiting dividend growth. 2) Competitive risk: BDX faces intense competition in hospital supplies and infusion pumps, and its recent underperformance versus the S&P 500 (-22.9% over one year) suggests market share concerns. 3) Macro risk: low beta of 0.276 offers some defense, but healthcare sector rotation could pressure the stock. 4) Company-specific risk: high short interest (short ratio 5.76) indicates bearish sentiment and potential for volatility.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $210-225, assuming successful turnaround and margin recovery. Base case (55% probability) targets $185-200, assuming stabilization and meeting EPS estimates of $16.35. Bear case (20% probability) targets $130-150, assuming continued revenue decline and margin pressure. The base case is most likely, hinging on the company's ability to return to positive revenue growth and improve operating margins. Analyst average target of $195.67 aligns with our base case.
BDX appears undervalued on a forward basis but fairly valued on trailing metrics. The forward PE of 13.4x is below the broader market and its own historical average, suggesting the market expects earnings recovery. However, the trailing PE of 25.2x is elevated given the recent earnings decline, and the PEG ratio is negative due to lack of growth. The price-to-sales ratio of 1.93 and EV/EBITDA of 12.2 are in line with peers. Overall, the market is pricing in significant pessimism, but a re-rating depends on execution.
BDX may be a good buy for value investors willing to tolerate near-term uncertainty. The stock trades at a forward PE of 13.4x, well below its trailing PE of 25.2x, and offers a 2.84% dividend yield. Analyst consensus target of $195.67 implies 10% upside, but the recent 10.6% revenue decline and $311 million net loss are red flags. The risk/reward is balanced: potential upside to $225 if the turnaround succeeds, but downside to $130 if it fails. It is best suited for investors with a long-term horizon who believe in the company's ability to recover.
BDX is more suitable for long-term investment given its low beta (0.276), dividend yield (2.84%), and turnaround potential. The stock's recent volatility and earnings uncertainty make it less attractive for short-term trading. Long-term investors can benefit from the discounted forward PE and potential recovery, but should be prepared for a holding period of at least 2-3 years to allow the turnaround to materialize. Short-term traders might exploit the high short interest and volatility, but the risk is elevated.